Accelerating Innovation at Leica Biosystems

Purpose-Driven Portfolio Evolution Ind. EAS EAS 16% 22% 16% LS & LS LS TOTAL ANNUAL Env. REVENUE 18% ~$21B 33% Dx ~$20B -$28B 52% 40% Dx T&M Dental Dx 31% Dental 32% 13% 14% 13% 2015 2021E KEY PORTFOLIO PALL FORTIVE Envista cytiva MOVES SINCE 2015 INTEGRATED DNA TECHNOLOGIES Cepheid. 2018 XXIDT 2015 metrics shown include Fortive and Envista; 2018 metrics shown include Envista. Pie charts are shown as a % of total revenue. Portfolio has evolved meaningfully DANAHER

View entire presentation